

106. EPC Syntheses<sup>1)</sup> from Bicyclic Dioxanones: (–)-5-Epidehydrofukinone

by Bernardo Herradón


Laboratorium für Organische Chemie der Eidgenössischen Technischen Hochschule, ETH-Zentrum,  
Universitätstrasse 16, CH-8092 Zürich

(28. IV. 88)

(–)-5-Epidehydrofukinone ((–)-**15**) has been synthesized from (2*S*,4*aS*,5*S*,8*aS*)-4*a*,5-dimethyl-2-(*tert*-butyl)-perhydro-4*H*-1,3-benzodioxan-4-one (**4a**), a compound readily available by yeast reduction of ethyl 2-oxocyclohexanecarboxylate.

Recently [2], we have synthesized derivatives of (1*S*,2*S*)-2-hydroxycyclohexanecarboxylic acid with three contiguous stereogenic centers (compounds **5**, *Scheme 1*) from (1*R*,2*S*)-2-hydroxycyclohexanecarboxylic acid (**1**). The method is based on a highly stereoselective *Michael* addition of lithium dialkylcuprates to the  $\alpha,\beta$ -unsaturated lactone **2** and trapping of the resulting enolates with electrophiles, aqueous  $\text{NH}_4\text{Cl}$  solution, or alkyl halides, giving single diastereoisomers **3** and **4**, respectively.

In [2], the products of double alkylation were tentatively assigned a *cis*-fused perhydro-4*H*-1,3-benzodioxin-4-one structure (see **6** in *Scheme 1*). In this note, we describe the

*Scheme 1*


<sup>1)</sup> For definition and discussion of the term, see [1].

<sup>2)</sup> On leave from the *Instituto de Química Orgánica General-C. S. I. C.*, Spain.

transformation of compound **4a** to (–)-5-epidehydrofukinone (= (4*aS*,5*S*)-4,4*a*,5,6,7,8-hexahydro-4*a*,5-dimethyl-3-(1-methylethylidene)-2(3*H*)-naphthalenone; (–)-**15**), providing a chemical correlation which proves the (*S*)-configuration of C(4*a*) in the starting material. Thus, the two six-membered rings of **4a** and of the analogues **4b** and **4c** are *trans*- and not *cis*-fused.

The synthesis<sup>3)</sup> of (–)-5-epidehydrofukinone ((–)-**15**) from **4a** is shown in *Scheme 2*. The bicyclic dioxanone **4a** was first hydrolyzed to the crystalline  $\beta$ -hydroxy acid **5a** (m.p. 106°,  $[\alpha]_D = +51.1$ )<sup>4)</sup>, using acidic or basic conditions. This compound was methylated with ethereal CH<sub>2</sub>N<sub>2</sub>, in the usual conditions, yielding **6** ( $[\alpha]_D = +65.4$ ). The protected

Scheme 2



a) Dowex 50  $\times$  8, MeOH, r.t., 94%, or LiOH, THF, MeOH, H<sub>2</sub>O, r.t., > 98%. b) CH<sub>2</sub>N<sub>2</sub>, Et<sub>2</sub>O, 0°, > 99%. c) ClCH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>SiMe<sub>3</sub> (= SEM-Cl), (i-Pr)<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, r.t., > 98%. d) LiAlH<sub>4</sub>, THF, 0°, 91%. e) PCC, 4 Å molecular sieves, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 94%. f) 1) CH<sub>2</sub>COCH<sub>2</sub>LiK, Et<sub>2</sub>O, from –45° to r.t.; 2) 2*N* HCl, 0°, 73–83%. g) LiBF<sub>4</sub>, MeCN, 70°, 74%. h) PCC, 4 Å molecular sieves, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 84%. i) H<sub>2</sub>, Pd/C (cat.), EtOAc, r.t., 91%. j) 1) NaOMe, MeOH, r.t.; 2) TsOH, CH<sub>2</sub>Cl<sub>2</sub>, 92%. l) 1) LiN(i-Pr)<sub>2</sub>, THF, from –50 to –38°; ZnCl<sub>2</sub>, –38°; acetone, –38 to 0°; 2) TsOH, C<sub>6</sub>H<sub>6</sub>, reflux, 77%.

$\beta$ -hydroxy ester **7** ( $[\alpha]_D = -6.4$ ), which was prepared by reaction with [2-(trimethylsilyl)-ethoxy]methyl chloride (SEM-Cl) using standard conditions [3], was reduced to the corresponding alcohol **8** ( $[\alpha]_D = +81.7$ ), which in turn was oxidized to aldehyde **9** ( $[\alpha]_D = +50.3$ ), using pyridinium chlorochromate (= PCC) [4] in the presence of 4 Å molecular sieves [5]. The chain elongation was complicated by the low reactivity and unstability of the aldehyde **9**. Wittig reaction of **9** with (acetylmethylidene)triphenylphosphorane under several different conditions<sup>5)</sup> gave no olefinic compounds, but rather

<sup>3)</sup> All the new compounds gave satisfactory spectroscopic data (<sup>1</sup>H-NMR, IR, and MS).

<sup>4)</sup> All optical rotations were measured at 25° and with concentrations of ca. 1 g/100 ml in CHCl<sub>3</sub> solution, except for compound **5a**, which was measured in MeOH solution.

<sup>5)</sup> Toluene, MeCN, and MeOH [6] were used as solvent at different temperatures.

decomposition products; finally, this transformation could be achieved by reaction with doubly deprotonated acetone [7], and quenching with 2N aqueous HCl, to give compound **10** ( $[\alpha]_D = +66.8$ ) as a single stereoisomer in *ca.* 80% yield.

The next step consisted of deprotection of the OH group; it was more difficult than expected: treatment of **10** with  $\text{Bu}_4\text{NF}$  [3] under a variety of conditions caused decomposition. The transformation was eventually accomplished with 10 equiv. of  $\text{LiBF}_4$  in MeCN at 70° for 8 h [8], with isolation of alcohol **11**, in acceptable purity, by distillation from the crude product mixture. Crude compound **11** was directly oxidized to the diketone **12** ( $[\alpha]_D = +204.0$ ), which in turn was hydrogenated to give the saturated diketone **13** ( $[\alpha]_D = 97.1$ ). Intramolecular aldol condensation with **13** was again tried under a set of different conditions<sup>6)</sup>, with the best results being observed by sequential treatment with NaOMe in MeOH<sup>7)</sup> and TsOH in  $\text{CH}_2\text{Cl}_2$ , affording **14** ( $[\alpha]_D = -192.0$ ) in high yield.

Reaction of the enolate of octalone **14**, as generated by treatment with  $\text{LiN}(\text{i-Pr})_2$ , with acetone [10] in the presence of  $\text{ZnCl}_2$  [11] gave a 9:1 mixture of aldols (yield: 80%), treatment of which with a catalytic amount of TsOH in refluxing benzene afforded (–)-5-epidehydrofukinone ((–)-**15**; 60%), besides **14** (37%, retroaldol reaction!) which were easily separated by prep. TLC. Spectroscopic data<sup>8)</sup> of (–)-5-epidehydrofukinone agree with those reported for racemic **15** [12].

In conclusion, (–)-5-epidehydrofukinone has been synthesized from the dioxanone **4a** in 13 steps<sup>9)</sup> (28% overall yield). This synthesis also shows that the chiral building blocks available from the bicyclic dioxanone **2** can be used for EPC syntheses of more complex molecules. Work applying compounds **3** and **4** in natural-product synthesis is in progress.

I thank Professor D. Seebach for encouragement and financial support, the *Ministerio de Educacion y Ciencia*, Spain, for a fellowship and Dr. I. Solana, University of Zürich, for measuring the  $^{13}\text{C}$ -NMR spectrum of (–)-**15**.

<sup>6)</sup> The use of catalytic amounts of piperidinium acetate in refluxing benzene [9] or of pyridinium *p*-toluenesulfonate in refluxing toluene (in the presence of molecular sieves) led to compound **14** in unsatisfactory yields.

<sup>7)</sup> At this stage, a single aldol-type product, of unknown configuration, could be isolated.

<sup>8)</sup> Data of (–)-(**15**): M.p. 63–64°.  $[\alpha]_D = -178.0$ . IR (KBr): 1660, 1620, 1610.  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 300 MHz): 0.95 (*d*, *J* = 7.1, 3 H); 1.18 (*d*, *J* = 0.7, 3 H); 1.46 (*m*, 1 H); 1.66 (*m*, 2 H); 1.79 (*m*, 1 H); 1.83 (*d*, *J* = 1.2, 3 H); 1.94 (*m*, 1 H); 2.09 (*d*, *J* = 2, 3 H); 2.27 (br. *d*, *J* = 13.5, 1 H); 2.34 (*m*, 2 H); 2.55 (br. *d*, *J* = 13.5, 1 H); 5.81 (*d*, *J* = 2, 1 H).  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 100 MHz): 16.3, 20.9, 22.2, 22.5, 24.3, 28.7, 31.0, 38.7, 39.6, 42.0, 128.3, 128.9, 142.1, 166.9, 191.7. MS: 218 (100,  $M^+$ ), 203 (20).

<sup>9)</sup> All transformations, except for the preparation of **10** and **11**, could be carried out without purification of intermediates.

## REFERENCES

- [1] D. Seebach, E. Hungerbühler, in 'Modern Synthetic Methods', Ed. R. Scheffold, Salle and Sauerländer, Berlin, 1980, Vol. 2, pp. 91–171.
- [2] D. Seebach, B. Herradón, *Tetrahedron Lett.* **1987**, 28, 3791.
- [3] B. H. Lipshutz, J. J. Pegram, *Tetrahedron Lett.* **1980**, 21, 3343.
- [4] E. J. Corey, J. W. Suggs, *Tetrahedron Lett.* **1975**, 2647.
- [5] J. Herscovici, K. Antonakis, *J. Chem. Soc., Chem. Commun.* **1980**, 561.
- [6] a) S. Valverde, M. Martin-Lomas, B. Herradón, S. Garcia-Ochoa, *Tetrahedron* **1987**, 43, 1895; b) H. O. House, V. K. Jones, G. A. Frank, *J. Org. Chem.* **1964**, 29, 3327.
- [7] a) J. S. Hubbard, Th. M. Harris, *J. Am. Chem. Soc.* **1980**, 102, 2110; b) Ch. A. Brown, *J. Org. Chem.* **1974**, 39, 1324.
- [8] B. H. Lipshutz, D. F. Harvey, *Synth. Commun.* **1982**, 12, 267.
- [9] a) T. Harayama, M. Ohtani, M. Oki, Y. Inibushi, *Chem. Pharm. Bull.* **1973**, 21, 1061; b) R. B. Woodward, F. Sondheimer, D. Taub, K. Heusler, W. M. Mc Lamore, *J. Am. Chem. Soc.* **1952**, 74, 4223.
- [10] H. Hagiwara, H. Uda, T. Kodama, *J. Chem. Soc., Perkin Trans. 1* **1980**, 963.
- [11] H. O. House, D. S. Crumrine, A. Y. Teranishi, H. D. Olmstead, *J. Am. Chem. Soc.* **1973**, 95, 3310.
- [12] H. J. Reich, E. J. Eisenhart, R. E. Olson, M. J. Kelly, *J. Am. Chem. Soc.* **1986**, 108, 7791.